1858 Wealth Management LLC Lowers Stock Holdings in Boston Scientific Corporation $BSX

1858 Wealth Management LLC lessened its position in Boston Scientific Corporation (NYSE:BSX) by 4.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,882 shares of the medical equipment provider’s stock after selling 265 shares during the quarter. 1858 Wealth Management LLC’s holdings in Boston Scientific were worth $632,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. Vanguard Group Inc. lifted its position in shares of Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares in the last quarter. Swedbank AB lifted its position in shares of Boston Scientific by 114.5% in the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after acquiring an additional 1,505,019 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after acquiring an additional 1,383,524 shares in the last quarter. Finally, Ninety One UK Ltd lifted its position in shares of Boston Scientific by 33.5% in the second quarter. Ninety One UK Ltd now owns 5,146,218 shares of the medical equipment provider’s stock valued at $552,755,000 after acquiring an additional 1,290,414 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Barclays lifted their price objective on Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Evercore ISI reduced their price objective on Boston Scientific from $115.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Finally, Truist Financial lifted their price objective on Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and a consensus price target of $120.71.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 174,214 shares of company stock valued at $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.9%

Shares of NYSE BSX opened at $95.41 on Friday. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a fifty day simple moving average of $101.98 and a 200-day simple moving average of $101.86. The stock has a market capitalization of $141.38 billion, a PE ratio of 56.79, a PEG ratio of 2.30 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. The company’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.